Ocilrp2 costimulates T cell activation by activating MAPK signaling pathway

Event Abstract Back to Event Ocilrp2 costimulates T cell activation by activating MAPK signaling pathway Qiang Lou1, Guangchao Liu1, Yuanfang Ma1 and Yanzhong Hu1* 1 henan University school of medicine, China OCILRP2 is a typical Type-II transmembrane protein that is selectively expressed in the activated T lymphocyte, DC cell and B cells. It has been found to be a novel co-stimulator of T cell activation. However, the signaling pathways underlying OCILRP2 in the T cell activation are still not unclear. In this paper we found that shRNA silence OCILRP2 expression can inhibit the EL4 T cells’ proliferation and IL2 production and reduce the MAPK3 and MAPK8 activation and Lck’s tyrosine phosphorylation but not PI3K-AKT pathway. The antagonist OP2-antibody can partially impair the CD3/CD28-costimulated EL4 T cell activation, and inhibit the transcription factors NFAT, AP-1 and NF-kB activation. Furthermore, the immunoprecipitation results indicated that OCILRP2 could interact with DAP12 protein, an adaptor containing a intracellular ITAM motif that can transuduct the signal to the MAP kinase activation for T cell activation. Our data demonstrate that after binding to its ligands OCILRP2 and DAP12 forms heterodimer, which then activate the LCK-MAP kinases pathways and the transcription factors NFAT, AP-1 and NF-kB activation resulting in T cell activation. Acknowledgements This work is supported by National Nature Science Foundation of China (No.30972687). Keywords: Ocilrp2, co-stimulation of T cell activation, DAP12, MAP kinases, Lck Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Innate immunity Citation: Lou Q, Liu G, Ma Y and Hu Y (2013). Ocilrp2 costimulates T cell activation by activating MAPK signaling pathway. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00751 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 16 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. Yanzhong Hu, henan University school of medicine, kaifeng,henan, China, hyz@henu.edu.cn Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Qiang Lou Guangchao Liu Yuanfang Ma Yanzhong Hu Google Qiang Lou Guangchao Liu Yuanfang Ma Yanzhong Hu Google Scholar Qiang Lou Guangchao Liu Yuanfang Ma Yanzhong Hu PubMed Qiang Lou Guangchao Liu Yuanfang Ma Yanzhong Hu Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.